Skip to main content

Table 1 Baseline clinical characteristic of patients and controls

From: The relation between neutrophil-to-lymphocyte ratio and coronary chronic total occlusions

  Control group (n = 75) CAD group (n = 75) CTO group (n = 75) p
Age, years 58 ± 11 63 ± 10 61 ± 8 0.01
Male, n (%) 34 (45.3) 49 (65.3) 66 (88) <0.001
Diabetes mellitus, n (%) 12 (16) 30 (40) 26 (34.7) 0.004
Hypertension, n(%) 50 (66.7) 55 (73.3) 49 (65.3) 0.52
Hyperlipidemia, n (%) 19 (25.3) 44 (58.7) 52 (69.3) <0.001
Family history of CAD, n (%) 2 (2.7) 4 (5.3) 29 (38.7) <0.001
Smoking, n (%) 25 (33.3) 33 (44.4) 39 (52) 0.06
Ejection fraction, % 57.9 ± 7.4 55.1 ± 10 51.3 ± 9.1 <0.001
Hemoglobin, g/dL 14.2 ± 1.6 13.8 ± 1.6 13.7 ± 1.7 0.16
Platelet, 103/ml 233 ± 61 251 ± 75 233 ± 68 0.17
WBC, 103/ml 7.40 ± 1.84 7.93 ± 1.96 8.63 ± 1.94 0.001
Neutrophil, 103/ml 4.16 ± 1.27 4.78 ± 1.36 5.62 ± 1.49 <0.001
Lymphocyte,103/ml 2.46 ± 0.76 2.33 ± 0.67 2.11 ± 0.72 0.01
NLR 1.79 ± 0.57 2.13 ± 0.64 2.95 ± 1.29 <0.001
Gensini score 1.5 (0-13) 26 (2-128) 64 (33.5-158) <0.001
SYNTAX score   10.3 ± 6.8 19.2 ± 7.6 <0.001
  1. CAD, coronary artery disease; CTO, coronary total occlusion; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cell.
  2. Significant p values are bold.